Abstract
A prospective study was performed in patients with non-small cell lung cancer (NSCLC) to evaluate the prognostic importance of multiple molecular marker (p53, c-Ki-ras, c-erbB-2) testing. 103 patients with potentially curative resections (RO resection) for NSCLC in histopathological stages I–IIIA were included. SSCP analysis and DNA sequencing for p53 and c-Ki-ras genes were performed on paired tumour and normal lung tissue samples and immunohistochemistry (c-erbB-2) was done on frozen tissue sections with a specific anti-c-erbB-2 monoclonal antibody. 46/103 (44.6%) NSCLC showed p53 mutations and 17/103 (16.5%) c-Ki-ras mutations including 12/37 (32.4%) adenocarcinomas. Overexpression of c-erbB-2 (p185) was detected in 56/103 (54.4%) tumours. 24/103 (23.3%) NSCLC were negative for alterations in all 3 parameters (c-Ki-ras, p53 and p185) whereas 79/103 (76.7%) were positive for at least one of the 3 parameters. In a regression model including a multiple molecular marker parameter (negative for all 3 markers versus positive for at least one marker), histopathological stage (P< 0.00001), respectively the pT (P< 0.01) and pN (P< 0.00001) categories and the multiple molecular marker parameter (P< 0.01) were of significant prognostic importance. This study demonstrates that testing 3 molecular markers (c-Ki-ras, p53 and c-erbB-2) improves estimation of prognosis compared to single marker testing and appears to define low (82.6% ± 7.9% 5-year survival) and high risk (40.2% ± 5.5% 5-year survival) groups for treatment failure in potentially curative (RO) resected NSCLC. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Altman DG, Lausen B, Sauerbrei W and Schumacher M (1994) Dangers of using ‘optimal’ cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829–835
Boenisch T (1989) Staining methods, controls, background. Handbook Immunochemical Staining Methods, Dako Carpinteria 13–23
Bongiorno PF, Whyte RI, Lesser EJ, Moore JH, Orringer MB and Beer DG (1994) Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J Thorac Cardiovasc Surg 107: 590–595
Buelzebruck H, Bopp R, Drings P, Bauer E, Krysa S, Probst G, van Kaick G, Muller KM and Vogt-Moykopf I (1992) New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 70: 1102–1110
Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, McIntire D, Slamon D, Gazdar A and Minna J (1994) p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer: a preliminary report of Lesg 871. Chest 106: 377–381
Chiba I, Takahashi T, Nau MM, D DA, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S and Koga H (1990) Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group, Oncogene 5: 1603–1610
Chiu KY, Loke SL and Ho FC (1994) Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: comparison of cryostat and paraffin wax sections and effect of fixation. J Clin Pathol 47: 117–121
Cox DR (1972) Regression models and life-tables (with discussion). J R Stat Soc B 34: 187–220
Gazdar AF (1992) The molecular biology of lung cancer. Tohoku J Exp Med 168: 239–245
Hermanek P, Henson DE, Hutter RVP and Sobin LH (1993). UICC TNM Supplement, Springer Verlag: Berlin, Heidelberg, New York 9–14
Holmes EC (1994) General principles of surgery quality control. Chest 106: 334–336
Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, Shimokata K, Yamakawa K, Nakamura Y and Ueda R (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53: 1–4
Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ and Marks JR (1990) Increased c-erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50: 6701–6707
Imamura J, Bartram CR, Berthold F, Harms D, Nakamura H and Koeffler HP (1993) Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res 53: 4053–4058
Johnson BE (1995) Biologic and molecular prognostic factors-impact on treatment of patients with non-small cell lung cancer. Chest 107: 287–290
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 187–220
Keohavong P, DeMichele MA, Melacrinos AC, Landreneau RJ, Weyant RJ and Siegfried JM (1996) Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 2: 411–418
Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L and Robinson RA (1990) p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50: 5184–5187
Kern JA, Slebos RJ, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D and Schwartz DA (1994) C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93: 516–520
Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K and Sekiya T (1992) Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 52: 4799–804
Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Chemother Rep 50: 163–170
Minna JD (1993) The molecular biology of lung cancer pathogenesis. Chest 103: 449–456
Mitsudomi T, Steinberg SM, Oie HK, Mulshine JL, Phelps R, Viallet J, Pass H, Minna JD and Gazdar AF (1991) ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51: 4999–5002
Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R and Shirakusa T (1993) Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 85: 2018–2023
Mountain CF (1986) A new international staging system for lung cancer. Chest 89: 225–233
Mountain CF (1990) Expanded possibilities for surgical treatment of lung cancer. Survival in stage IIIa disease. Chest 97: 1045–1051
Naruke T, Goya T, Tsuchiya R and Suemasu K (1988) Prognosis and survival in resected lung carcinoma based on the new international staging system [published erratum appears in J Thorac Cardiovasc Surg 1989 Mar; 97(3):350]. J Thorac Cardiovasc Surg 96: 440–447
Parker SL, Tong T, Bolden S and Wingo PA (1996) Cancer statistics, 1996. CA Cancer J Clin 46: 5–27
Pfeiffer P, Clausen PP andersen K and Rose C (1996) Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 74: 86–91
Press MF, Hung G, Godolphin W and Slamon DJ (1994) Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54: 2771–2777
Quinlan DC, Davidson AG, Summers CL, Warden HE and Doshi HM (1992) Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828–>4231
Rodenhuis S and Slebos RJ (1992) Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52: 2665–2669
Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J and Olazabal A (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330: 153–8
Rosell R, Monzo M, Pifarre A, Ariza A, Sanchez JJ, Moreno I, Maurel J, Lopez MP, Abad A and De Anta JM (1996) Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin Cancer Res 2: 1083–1096
Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, Borresen AL and Haugen A (1994) p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res 54: 1551–1555
Sauter ER, Gwin JL, Mandel J and Keller SM (1995) p53 and disease progression in patients with non-small cell lung cancer. Surg Oncol 4: 157–161
Schneider PM, Hung MC, Chiocca SM, Manning J, Zhao XY, Fang K and Roth JA (1989) Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49: 4968–4971
Schneider PM, Casson AG, Levin B, Garewal HS, Hoelscher AH, Becker K, Dittler HJ, Cleary KR, Troster M, Siewert JR and Roth JA (1996) Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 111: 323–331, 331–333
Shi D, He G, Cao S, Pan W, Zhang HZ, Yu D and Hung MC (1992) Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcing 5: 213–218
Simon R and Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69: 979–85
Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van Zandwijk N and Mooi WJ (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323: 561–565
Spurrier JD and Hewett JE (1980) Two-stage test of independence using Kendall's statistic. Biometrics 36: 517–522
Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K and Sasazuki T (1992) ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52: 2903–2906
Tateishi M, Ishida T, Mitsudomi T, Kaneko S and Sugimachi K (1991) Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27: 1372–1375
Top B, Mooi WJ, Klaver SG, Boerrigter L, Wisman P, Elbers HR, Visser S and Rodenhuis S (1995) Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int J Cancer 64: 83–91
Volm M, Efferth T and Mattern J (1992) Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 12: 11–20
World Health Organization (1982) The World Health Organization histologic typing of lung tumors. Am J Clin Pathol 77: 123–136
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Schneider, P., Praeuer, H., Stoeltzing, O. et al. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 83, 473–479 (2000). https://doi.org/10.1054/bjoc.2000.1287
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1287
Keywords
This article is cited by
-
A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme
Journal of Neuro-Oncology (2014)
-
Relationship of immunohistochemical biomarker expression and lymph node involvement in patients undergoing surgical treatment of NSCLC with long-term follow-up
Tumor Biology (2014)
-
The expressions and clinical significance of P53, C-erbB-2 and VEGF in non-small cell lung cancer
The Chinese-German Journal of Clinical Oncology (2008)
-
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
British Journal of Cancer (2005)
-
Combined expression of p53, cyclin D1 and epidermal growth factor receptor improves estimation of prognosis in curatively resected oral cancer
Modern Pathology (2005)